Alder L et al. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ Breast Cancer 2023;9(1):19. Abstract
Bartsch R et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Neuro Oncol 2024;26(12):2157-8. Abstract
Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract
Darlix A et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 2019;121(12):991-1000. Abstract
Freedman R et al. Translational breast cancer research consortium trial 022: Neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases (BCBM). San Antonio Breast Cancer Symposium 2022;Abstract PD7-03.
Kabraji S et al. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clin Cancer Res 2023;29(1):174-82. Abstract
Lin NU et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results. ESMO 2024;Abstract LBA18.
Lin NU et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38(23):2610-9. Abstract
McTyre ER et al. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiother Oncol 2020;142:168-74. Abstract
Murthy RK et al. Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. San Antonio Breast Cancer Symposium 2021;Abstract PD4-02.
Niikura N et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer 2023;9(1):82. Abstract
O’Brien BJ et al. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. ASCO 2024;Abstract 2018.
Pérez-García JM et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol 2023;25(1):157-66. Abstract
Reese RA et al. Incidence and predictors of neurologic death in patients with brain metastases. World Neurosurg 2022;162:e401-15. Abstract
Sammons S et al. Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients. J Natl Cancer Inst 2025. Abstract
Sperduto PW et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012;82(5):2111-7. Abstract
Stavrou E et al. How we treat HER2-positive brain metastases. ESMO Open 2021;6(5):100256. Abstract
Stringer-Reasor EM et al. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. ASCO 2021;Abstract 1044.
Vaz Batista M et al. Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: Results from cohort 5 of the DEBBRAH study. San Antonio Breast Cancer Symposium 2023;Abstract PS11-05.